Patent · US Active

3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl) phenylamino]methyl}-1-methyl-1H-benzimidazol-5-carbonyl)pyridin-2-ylamino]propionic acid ethylester methansulfonate and its use as a medicament

US7932273B2 · kind B2 · utility

16Cited by

15References

2Claims

0Family size

Assignee

Boehringer Ingelheim International GmbH · DE

Inventors

Rolf Schmid · Gelterkinden, CH
Peter Sieger · Mittelbiberach, DE
Rainer Sobotta · Ingelheim am Rhein, DE

Key dates

Filing date	Jan 30, 2008
Grant date	Apr 26, 2011
Priority date	—
Expiry date	Feb 23, 2029

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P43/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Ethyl 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl)phenylamino]methyl}-1-methyl-1H-benzimidazole-5-carbonyl)pyridin-2-ylamino]propionate methanesulfonate in the crystalline modifications I and II and as the hemihydrate and the use thereof as a pharmaceutical composition.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.